Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Avanir's AVP-825 under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:20PM CDT
Avanir Pharmaceuticals announced that the New Drug Application for its migraine candidate, AVP-825, has been accepted by FDA.
Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
PR Newswire - Wed Mar 26, 8:00AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine.
Avanir Provides New Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:31PM CDT
Avanir announced that data revealing dextromethorphan has antidepressant-like effects in vivo was recently published in PLOS ONE.
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
PR Newswire - Fri Mar 21, 10:11AM CDT
The trading session on Thursday, March 20, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT). Free technical research on ZTS, MYL, AVNR and ACT can be downloaded upon signing up at:
Avanir Pharmaceuticals Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivo
PR Newswire - Thu Mar 20, 8:00AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the potential involvement of sigma-1 receptors. A link to the online article can be accessed at http://www.plosone.org/article/info%3Adoi%2F1...ne.0089985.
Avanir Pharmaceuticals names Dr Mark Corrigan to board
M2 - Thu Mar 20, 5:02AM CDT
Biopharmaceutical company Avanir Pharmaceuticals (NasdaqGS:AVNR) revealed on Wednesday the addition of Dr Mark Corrigan to its board of directors.
Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors
PR Newswire - Wed Mar 19, 3:00PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience.
Galena Biopharma Inc. Share Value Tumbles on News of SEC Investigation
ACCESSWIRE - Wed Mar 19, 10:25AM CDT
Galena Biopharma Inc. (NASDAQ:GALE) share volume soared Mar. 18, with more than 17,653,116 shares changing hands, nearly double its three-month average volume of 9,373,933 shares, while its share value continued to tumble, closing at $2.82, down 40 cents, or 12.42%, from its closing price of $3.22 the previous day. The high volume and stock value tumble are being triggered by the Worcester, Mass-based company's revelation that it is being investigated by the Securities and Exchange Commission. Here is the company's statement: "In February 2014, we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation," the company stated in its 10-K filing dated Mar. 17. Class-Acton Lawsuits In addition to this bad news, the company is facing a slew of class action lawsuits from stockholders that allege Galena and certain of its executives issued a series of materially false and misleading statements during the Class Period, violating federal securities laws. However, it should be noted that none of these allegations have been proven. Moreover, Galena's results for its fourth quarter were less than comforting to shareholders. Its earnings per share loss of (46c) on revenue of $1.32M as compared to estimates of (9c) and $1.62M, respectively. The company pointed out that the Q4 net loss of $48.5M included $38.9M in non-cash charges. On the positive side, the company lifted its 2014 Abstral net revenue estimates to $11M-$15M as compared to prior guidance of $8M-$12M. Analysts' Consensus Nonetheless, of the 9 analyst firms that cover Galena, 7 rate it a "strong buy," 1 a "buy" and 1 a "sell." Find out what could be the best investor's move when it comes to GALE by getting the complete report here, or by cutting and pasting the following link in your Web browser: http://www.sixfigurestockpicks.com Bioheart Inc.'s Stock Volume Soars on News of Joint Venture with Magnum Cell Therapies Meanwhile, development-stage, biotechnology company Bioheart Inc.'s (OTCQB: BHRT) stock volume continued to soar Mar. 18, with 7,457,880 shares changing hands, nearly three times more than its three-month average volume of 2,607,553 shares.
Avanir Pharmaceuticals Presents Data from a Benchmark Study of PBA Symptoms in Veterans with Mild Traumatic Brain Injury
PR Newswire - Wed Mar 19, 8:40AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury (TBI) conducted in collaboration with the Department of Veterans Affairs (VA) and Evidera. The study will be presented at the Tenth World Congress on Brain Injury in San Francisco on Friday March 21, 2014.
Avanir (AVNR) Catches Eye: Stock Soars 16.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:25AM CST
Avanir was a big mover last session, as the company saw its shares rise over 16% on the day.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AVANIR Pharmaceuticals Up 5.5%, Shares Break Through Resistance (AVNR)
Comtex SmarTrend(R) - Wed Mar 05, 10:12AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 5.5% to $4.54 on 1.0x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.1 million shares, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
MannKind Corp.'s Share Value Increases 74% on News of FDA's Preliminary Approval
ACCESSWIRE - Mon Mar 03, 8:42AM CST
On Apr. 2, MannKind Corp. (NASDAQ:MNKD) stock volume and share value shot through the roof on news that a FDA panel granted market approval for the biotech company's inhalable insulin.
Avanir Pharmaceuticals to Participate in Two Conferences in March
PR Newswire - Fri Feb 28, 8:00AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
Hot Stock: AVANIR Pharmaceuticals, Shares Gain 6.5% (AVNR)
Comtex SmarTrend(R) - Wed Feb 26, 11:41AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 6.5% to $4.09 on 1.3x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.5 million shares, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (6.5% to the Dow's 0.3%) and outperformed the S&P 500 (6.5% to the S&P's 0.3%) during today's trading.
Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 7:00AM CST
Avanir Pharmaceuticals had high hopes for AVP-923, a neuropathy pain treatment for Alzheimer's, Parkinson's, and autism. However, AVP-923 failed to do better than placebo in a key mid-stage multiple sclerosis trial, disappointing investors and...
Will Mallinckrodt's Xartemis Change How We Treat Pain?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 14, 12:36PM CST
is having a stellar run since being spun-off by Covidien last summer. The split-up is unlocking value at both companies as Covidien focuses on its medical device business and Mallinckrodt advances new pain killing compounds to market. So far,...